Harvard University
Cambridge, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Migraine
FollowWhat is new in Migraine research, which clinical trials are open, and who works on it. From public registries and PubMed, with the source and date of every fact.
Cure status
- 0.5% Bupivacaine HClPhase 3 · NCT06937385
- 270mg IdebenonePhase 3 · NCT04151472
- 90mg IdebenonePhase 3 · NCT04151472
- Aspirin and clopidogrelPhase 3 · NCT04946734
- AtogepantPhase 3 · NCT05707949 · NCT05711394 · NCT06806293 · NCT06810505
- Botulinum toxin type APhase 3 · NCT06047457 · NCT06047444
- BR005-036CPhase 3 · NCT07792681 · NCT07835152
- CGRP mAbs and onabotulinumtoxin APhase 3 · NCT07040813
- CGRP mAbs and placeboPhase 3 · NCT07040813
- ElismetrepPhase 3 · NCT07645924 · NCT07674654 · NCT07816367
- EptinezumabPhase 3 · NCT04965675 · NCT06428838 · NCT05897320 · NCT07191145 · NCT05164172
- Erenumab Dose 1Phase 3 · NCT03836040
- Erenumab Dose 2Phase 3 · NCT03836040
- Erenumab Dose 3Phase 3 · NCT03836040
- GalcanezumabPhase 3 · NCT04616326 · NCT03432286
- Gou-Teng-SanPhase 3 · NCT07496034
- IncobotulinumtoxinA (XEOMIN®)Phase 3 · NCT05598723
- KetaminePhase 3 · NCT05306899
- MagnesiumPhase 3 · NCT06904287
- Magnesium 400MgPhase 3 · NCT07147972
- Matching placeboPhase 3 · NCT04649242
- OnabotulinumtoxinA (BOTOX®)Phase 3 · NCT05598723
- PFO closure devicePhase 3 · NCT04946734
- Prasugrel 5mgPhase 3 · NCT07629635
- Propranolol 80 mgPhase 3 · NCT07147972
- RimegepantPhase 3 · NCT07667621 · NCT06616194 · NCT05156398 · NCT06641466 · NCT06748664 · NCT07729462 · NCT07751497 · NCT06992674
- Rimegepant (PF-07899801)Phase 3 · NCT04743141
- Rimegepant/BHV3000Phase 3 · NCT04649242
- standard IV treatment for headachePhase 3 · NCT06937385
- Transcatheter Closure of Patent Foramen OvalePhase 3 · NCT07629635
- Transcranial Direct Current stimulationPhase 3 · NCT07743814
- TriptansPhase 3 · NCT04946734
- UbrogepantPhase 3 · NCT06417775 · NCT05125302 · NCT05127954
- XeominPhase 3 · NCT07018713 · NCT07018700
- AmiloridePhase 2 · NCT04063540
- ASY202Phase 2 · NCT07646613
- Atorvastatin 20mgPhase 2 · NCT06248671
- Atorvastatin 40mgPhase 2 · NCT06485336 · NCT06248671
- Bupivacaine HCl 0.5% Injectable SolutionPhase 2 · NCT05734625
- Cabergoline 0.5 MGPhase 2 · NCT07072910
- Cabergoline 1 MGPhase 2 · NCT07072910
- CBD 100 mg ODPhase 2 · NCT03972124
- CBD 200 mg ODPhase 2 · NCT03972124
- CorabotasePhase 2 · NCT06625060
- Corabotase dose APhase 2 · NCT06625060
- Corabotase dose BPhase 2 · NCT06625060
- EVO756, Dose 1Phase 2 · NCT07616128
- EVO756, Dose 2Phase 2 · NCT07616128
- Exparel (Bupivacaine Liposome)Phase 2 · NCT04930887
- FlunarizinePhase 2 · NCT07751497
- Four tablets of NB001Phase 2 · NCT07577050
- Four tablets of placeboPhase 2 · NCT07577050
- Lidocaine (drug)Phase 2 · NCT07061847 · NCT07361549
- Lidocaine ProcedurePhase 2 · NCT07061847
- MEDI0618Phase 2 · NCT06602479
- Methylprednisolone 40 MG InjectionPhase 2 · NCT05734625
- MPL-001Phase 2 · NCT05337033
- One tablet of NB001 plus three tablets of placeboPhase 2 · NCT07577050
- PRT-064040 nasal sprayPhase 2 · NCT07304518
- SalinePhase 2 · NCT04930887 · NCT07361549
- Saline 0.9%Phase 2 · NCT07764783
- Topical solution of 4% lidocainePhase 2 · NCT07764783
- Two tablets of NB001 plus two tablets of placeboPhase 2 · NCT07577050
- AcupuncturePhase 1/2 · NCT06716944
- Glycerol TributyratePhase 1/2 · NCT06792500
- Flunarizine HydrochloridePhase 1 · NCT07068815
- Fu's Subcutaneous NeedlingPhase 1 · NCT07068815
- High Flow OxygenPhase 1 · NCT03511846
- Intranasal capsaicinPhase 1 · NCT03511846
- Low Flow OxygenPhase 1 · NCT03511846
- Oral capsaicinPhase 1 · NCT03511846
- Topical capsaicinPhase 1 · NCT03511846
- ZavegepantPhase 1 · NCT07667621 · NCT06995729
- Dexamethasone OralEarly phase 1 · NCT06016465
- Dextrose 5% in waterEarly phase 1 · NCT06935552
- Ketamine infusionEarly phase 1 · NCT06935552
- Lidocaine Intravenous InfusionEarly phase 1 · NCT06935552
- PsilocybinEarly phase 1 · NCT06464367
- Virtual RealityEarly phase 1 · NCT07374640
Closest to patients
- Effectivity and Safety of PFO Closure vs Medicine in Alleviating MigraineEffectivity and Safety of PFO Closure vs Medicine in Alleviating MigraineThe First People's Hospital of Nanning · Nanning, China + 19 more hospitalsPhase 3Primary completion 2025
- A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigraineA Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic MigraineClinical Integrative Research Center of Atlanta, LLC · Atlanta, United States + 73 more hospitalsPhase 3Primary completion 2025
- Efficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineEfficacy and Safety of Erenumab in Pediatric Participants With Episodic MigraineSolano y Terront Servicios Medicos SAS - Unidad Integral de Endocrinologia Uniendo · Bogota, Colombia + 32 more hospitalsPhase 3Primary completion 2025
Let us optimize your content
Apply for experimental treatment or a research study
The trial team decides who can take part; your doctor can help you ask.
Distance is calculated in your browser. Your city is not sent to us.
Loading trial sites…
Latest news
Results, new trials and publications, newest first. Every item links to its source.
Results and new studies, newest first, in plain words.
Plain-language summary pending. Original title shown.
Review
Ketogenic Diet and Neurological Health: A Narrative Review with Natural Language Processing-Assisted Thematic Mapping Using BERTopic.
Ketogenic Diet and Neurological Health: A Narrative Review with Natural Language Processing-Assisted Thematic Mapping Using BERTopic.
Neuropsychiatric disease and treatment
PubMed · PMID 42877272Preprint
Omega-3 Supplementation with Lipid Biomarker Assessment in Youth with Migraine: A Quasi-Randomized Controlled Feasibility Trial.
Omega-3 Supplementation with Lipid Biomarker Assessment in Youth with Migraine: A Quasi-Randomized Controlled Feasibility Trial.
medRxiv : the preprint server for health sciences
PubMed · PMID 42818883Randomised trial
Omega-3 Supplementation Modulates Whole-Blood EPA and DHA Without Improving Patient-Reported Outcomes in Youth with Migraine: A Quasi-Randomized Pilot Trial.
Omega-3 Supplementation Modulates Whole-Blood EPA and DHA Without Improving Patient-Reported Outcomes in Youth with Migraine: A Quasi-Randomized Pilot Trial.
Nutrients
PubMed · PMID 42796966Publication
Vitamin D concentrations and neutrophil-to-lymphocyte ratio are associated with disability and pain sensitivity in individuals with migraine: a cross-sectional study.
Vitamin D concentrations and neutrophil-to-lymphocyte ratio are associated with disability and pain sensitivity in individuals with migraine: a cross-sectional study.
Nutrition research (New York, N.Y.)
PubMed · PMID 42762793Publication
Body Mass Index Protects Against Temporomandibular Disorders, Whereas Systemic Inflammation, Vitamin D, and Migraine Do Not: A Causal Inference Study.
Body Mass Index Protects Against Temporomandibular Disorders, Whereas Systemic Inflammation, Vitamin D, and Migraine Do Not: A Causal Inference Study.
Pain research & management
PubMed · PMID 42972886
Find fellow researchers
Groups with active Migraine work.
University of Copenhagen
Copenhagen, Denmark
Team details appear once the team leader joins.
Is this your team? Claim it
Mayo Clinic
Rochester, United States
Team details appear once the team leader joins.
Is this your team? Claim it
Albert Einstein College of Medicine
Bronx, United States
Team details appear once the team leader joins.
Is this your team? Claim it
King's College London
London, United Kingdom
Team details appear once the team leader joins.
Is this your team? Claim it
Rigshospitalet
Copenhagen, Denmark
Team details appear once the team leader joins.
Is this your team? Claim it
Copenhagen University Hospital
Copenhagen, Denmark
Team details appear once the team leader joins.
Is this your team? Claim it
Sapienza University of Rome
Rome, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
Capital Medical University
Beijing, China
Team details appear once the team leader joins.
Is this your team? Claim it
Pfizer (United States)
New York, United States
Team details appear once the team leader joins.
Is this your team? Claim it
University of Pavia
Pavia, Italy
Team details appear once the team leader joins.
Is this your team? Claim it
University of L'Aquila
L’Aquila, Italy
Team details appear once the team leader joins.
Is this your team? Claim it